Measurement of soluble Fcγ receptor type IIIa derived from macrophages in plasma: Increase in patients with rheumatoid arthritis

Clinical and Experimental Immunology

Volumn 132, Issue 3, 2003, Pages 477-484

  Masuda, M ^a   Morimoto, T ^a   Kobatake, S ^b   Nishimura, N ^a   Nakamoto, K ^a   Dong, X H ^a   Komiyama, Y ^a   Ogawa, R ^a   Takahashi, H ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b FUJIFILM Wako Pure Chemical Corporation   (Japan)

Author keywords

Fc receptors; Human; Monocytes macrophages; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; FC RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GRM1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; ADULT; AGED; BLOOD; FEMALE; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED; SOLUBILITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, IGG; SOLUBILITY;

EID: 0037795626     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02168.x     Document Type: Article

References (22)

1. Ravetch JV, Perussia BV. Alternative membrane forms of FcγRIII (CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989; 170:481-97.
2. de Haas M, Kleijer M, Minchinton RM et al. Soluble FcγRIIIa is present in plasma and is derived from natural killer cells. J Immunol 1994; 152:900-7.
3. Harrison D, Phillips JH, Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated FcγRIII (CD16-II). J Immunol 1991; 147:3459-65.
4. Levy PC, Utell MJ, Fleit HB et al. Characterization of human alveolar macrophages Fc receptor Ill. A transmembrane glycoprotein that is shed under in vitro culture conditions. Am J Resp Cell Mol Biol 1991; 5:307-14.
5. Huizinga TW, de Haas M, van Oers MH et al. The plasma concentration of soluble FcγRIII is related to production of neutrophils. Br J Haematol 1994; 87:459-63.
6. Homburg CHE, de Haas M, von dem Borne AEGKr et al. Human neutrophils lose their surface FcγRIII and acquire Annexin V binding sites during apoptosis in vitro. Blood 1995; 85:532-40.
7. Middelhoven PJ, van Buul JD, Hordijk PL, Roos D. Different proteolytic mechanisms involved in FcγRIIIb shedding from human neutrophils. Clin Exp Immunol 2001; 125:169-75.
8. Brinckerhoff CE. Joint destruction in arthritis: metalloproteases in the spotlight. Arthritis Rheum 1991; 34:1073-5.
9. + effector cells by rheumatoid factor complex: role of natural killer cells in rheumatoid arthritis. Arthritis Rheum 1991; 34:423-31.
10. Tak PP, Kummer JA, Hack CE et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994; 37:1735-43.
11. Bhatia A, Blades S, Cambridge G, Edwards JCW. Differential distribution of FcγRIIIA in normal human tissues and colocalisation with DAF and fibrillin-1. Immunology 1998; 94:56-63.
12. Kirkham BW, Navarro FJ, Corkill MM, Panayi GS. In vivo analysis of disease modifying drug therapy activity in RA by sequential immunohistological analysis of synovial membrane interleukin 1β. J Rheumatol 1994; 21:1615-9.
13. Yanni G, Nabil M, Farahat MR et al. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis 1994; 53:315-22.
14. Smith MD, Kraan MC, Slavotinek J et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatol 2001; 40:367-74.
15. Sautès C, Teillaud C, Mazieres N et al. Soluble Fcγ receptors (sFcγR). Detection in biological fluids; production of a murine recombinant sFcγR biologically active in vitro and in vivo. Immunobiology 1992; 185:207-21.
16. Galon J, Moldovan I, Galinha A et al. Identification of the cleavage site of plasma soluble Fcγ receptor type III (CD16). Eur J Immunol 1998; 28:2101-7.
17. Koene HR, de Haas M, Kleijer M et al. NA-phenotype-dependent differences in neutrophil FcγRIIIb expression cause differences in plasma levels of soluble FcγRIII. Br J Haematol 1996; 93:235-41.
18. de Haas M, Kleijer M, von Roos D, von dem Borne AEGKr. Characterization of MAbs of the CD16 cluster and six new generation CD16 MAbs. In: Schlossmann SF et al. eds. Leukocyte typing V. Oxford: Oxford University Press, 1995:811-7.
19. Masuda M, Nakamura S, Murakami T et al. Association of tissue factor with a γ-chain homodimer of the IgE receptor type I in cultured human monocytes. Eur J Immunol 1996; 26:2529-32.
20. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
21. Koene HR, Kleijer M, Roos D et al. FcγRIIIB gene duplication. Evidence for presence and expression of three distinct FcγRIIIB genes in NA (1+, 2+) SH (+) individuals. Blood 1998; 91:673-9.
22. Furuya D, Yagihashi A, Yajima T et al. An immuno-polymerase chain reaction assay for human interleukin-18. J Immunol Meth 2000; 238:173-80.4